Screener
Aclaris Therapeutics ACRS Drug Candidate Ati052 — Research And Development Project Spend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:ResearchAndDevelopmentProjectSpend.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| (In thousands) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Cost of revenue | 218 | 515 | 613 | 1,021 |
| Research and development: | ||||
| Bosakitug | 3,335 | 2,847 | 6,476 | 6,231 |
| ATI-052 | 4,899 | 1,418 | 8,080 | 2,037 |
| Modzatinib | 370 | 1,118 | 861 | 2,926 |
| ATI-9494 | 3,056 | 871 | 5,281 | 1,549 |
| Discovery | 1,972 | 749 | 3,411 | 1,417 |
| Total research and development project expense(1) | 13,632 | 7,003 | 24,109 | 14,160 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's drug candidate ati052 — research and development project spend?
- Aclaris Therapeutics (ACRS) reported drug candidate ati052 — research and development project spend of $4.9M in Q2 2026.
- How has Aclaris Therapeutics's drug candidate ati052 — research and development project spend changed year-over-year?
- Aclaris Therapeutics's drug candidate ati052 — research and development project spend increased by 245.5% year-over-year, from $1.42M to $4.9M.
- What does drug candidate ati052 — research and development project spend mean?
- This metric represents the total direct costs and allocated resources dedicated to the research and development activities of a specific drug candidate within the company's clinical pipeline. It reflects the capital intensity and strategic priority assigned to advancing this particular therapeutic asset through preclinical or clinical stages. Monitoring this spend helps investors assess the company's commitment to specific immuno-inflammatory programs and the potential for future value creation through successful drug development.
Ask your AI about Aclaris Therapeutics's drug candidate ati052 — research and development project spend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude